Get the Stockscreener App
1.015
0.50%
0.005
Cognition Therapeutics Inc stock is traded at $1.015, with a volume of 395.02K.
It is up +0.50% in the last 24 hours and up +5.64% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
See More
Previous Close:
$1.01
Open:
$1.01
24h Volume:
395.02K
Relative Volume:
0.29
Market Cap:
$96.52M
Revenue:
-
Net Income/Loss:
$-19.58M
P/E Ratio:
-3.9387
EPS:
-0.2577
Net Cash Flow:
$-20.25M
1W Performance:
-3.33%
1M Performance:
+5.64%
6M Performance:
-9.38%
1Y Performance:
-34.09%
1-Day Range:
$1.01
$1.035
1-Week Range:
$0.9997
$1.10
52-Week Range:
$0.5501
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.015 | 96.04M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
514.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.61 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.05 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.65 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
361.72 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey
Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative
Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK
Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView
Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance
Cognition Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) to Post Quarterly Earnings on Thursday - MarketBeat
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.941|Chg%:+0.021 - TradingKey
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
CGTX|Cognition Therapeutics Inc|Price:0.929|Chg%:+0.010 - TradingKey
Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr
CGTX Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesEstimate Accuracy - po-news-eg.net
Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support LevelRVOL Breakout - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion - Quiver Quantitative
Alzheimer’s drug developer to outline Lewy body dementia Phase 3 plan - Stock Titan
Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Can AI automation provide a survival tool amid managed care's thin margins? (CVS:NYSE) - Seeking Alpha
Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Number of shareholders of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Price to earnings forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA) - The Globe and Mail
Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment - Investing.com South Africa
Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in FocusTrading Ideas - dars.gov.et
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo
Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cognition Therapeutics Inc Stock (CGTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ricciardi Lisa | CEO & President |
Apr 16 '26 |
Buy |
1.10 |
9,175 |
10,092 |
1,715,851 |
| Caggiano Anthony | Chief Medical Officer |
Apr 16 '26 |
Buy |
1.11 |
10,000 |
11,100 |
874,906 |
| Fletcher Aaron G.L. | Director |
Sep 19 '25 |
Option Exercise |
0.84 |
7,729 |
6,492 |
56,229 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):